JP Morgan has recently reduced Editas Medicine Inc (EDIT) stock to Underweight rating, as announced on December 16, 2024, according to Finviz. Earlier, on December 13, 2024, Truist had reduced the ...

Editas Medicine Inc (EDIT) stock saw a decline, ending the day at $1.38 which represents a decrease of $-0.03 or -2.13% from the prior close of $1.41. The stock opened at $1.41 and touched a low of $1 ...

Analysts at Zacks Research decreased their FY2024 earnings per share (EPS) estimates for Editas Medicine in a report issued on Tuesday, January 21st. Zacks Research analyst A. Chakraborty now expects ...

Equities research analysts at Leerink Partnrs decreased their FY2025 earnings per share (EPS) estimates for Editas Medicine in a note issued to investors on Wednesday, January 22nd. Leerink Partnrs ...

BioMed Realty, one of the biggest labspace owners in the Boston area, recently acquired 215 First St., 150 Second St. and 11 ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Editas Medicine has decided to end the development of its gene-editing therapy for thalassaemia and sickle cell disease (SCD), narrowing its R&D focus and making sweeping cuts to its workforce.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Earnings are arguably the most important single number on a company's quarterly financial report. Wall Street clearly dives into all of the other metrics and management's input, but the EPS figure ...

Build financial models with decades of earnings stats, ratios, and valuation data — all exportable — to power your trade ideas.

“This dosing is a truly historic event – for science, for medicine, and most importantly for people living with this eye disease,” said Cynthia Collins, Editas’ chief executive. LCA is a ...